An observational study in Diabetes Mellitus, Type 1, sponsored by Provention Bio, a Sanofi Company. Active, not recruiting at 47 sites in 8 countries. Open to participants aged 9 Years to 19 Years. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Provention Bio, a Sanofi Company (part of Sanofi) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 2 that started in 2020, is one of 6 observational ones, and was the 56th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Germany, Israel and 1 more country
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Sanofi · Sites in Kuwait, Saudi Arabia, United Arab Emirates
Ages 18 mo–18 yrs · Healthy volunteers
Sanofi · Sites in United States
Ages 8+
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
By country, each count listing its studies:
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 9 Years to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 6 · Phase 3 20 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 86 across the 60 interventional studies, 194 across the 6 observational. Of the 56 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Provention Bio, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Provention Bio, a Sanofi Company is the lead sponsor of 4 studies on the registry; none are open to participants now.
5 of the studies in Diabetes Mellitus, Type 1 by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT06812988SanofiTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | 2027-04-29 |
| NCT07038473SanofiEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
This study is the long-term extension of the PRV-031-001 (PROTECT) study. PROTECT is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1 diabetes (within 6 weeks of diagnosis) in which approximately 300 participants were randomized at a ratio of 2:1 to the teplizumab or placebo and received two courses of treatment administered 6 or 12 months apart with final follow-up at approximately 18 months (78 weeks) after the first dose.
Participants who complete the PROTECT study are invited to enroll in this observational, extension study to collect long-term safety and other clinical data. The decision to participate can be made within 12 months of completing the PROTECT study.
No study drug will be administered during this extension study. Participants will continue to receive standard care for type 1 diabetes from their primary physicians.
Participants will return to the study sites for assessments once every 6 months through Month 42. Therefore, the combined duration of the PROTECT and PROTECT Extension studies will be 60 months.
Participants who completed the PROTECT (PRV-031-001) study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Premature discontinuation from the PRV-031-001 (PROTECT) study for any reason.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received teplizumab in the PROTECT study
Biological: Teplizumab
Participants who received placebo in the PROTECT study
Other: Placebo
Received teplizumab in PROTECT Study
Received placebo in PROTECT study
Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies
Safety outcome
Time frame: During 42 months of follow-up
Area under the time-versus concentration curve (AUC) of C-peptide after a 4-hour (4h) mixed-meal tolerance test (MMTT)
Clinical parameters of diabetes management 1
Time frame: During the 42 months of follow-up
Insulin use (daily average insulin dose in U/kg/day)
Clinical parameters of diabetes management 2
Time frame: During the 42 months of follow-up
HbA1c
Clinical parameters of diabetes management 3
Time frame: During the 42 months of follow-up
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Nov 2026, 73 months after the start.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 73 months is above that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.